Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation.[6][7] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots.[6] It is used as an alternative to warfarin and does not require monitoring by blood tests.[6] In a meta analysis of 7 different studies, there was no benefit of dabigatran over warfarin in preventing ischemic stroke; however, dabigatran were associated with a lower hazard for intracranial bleeding compared with warfarin, but also had a higher risk of gastrointestinal bleeding relative to warfarin.[8] It is taken by mouth.[6]
Common side effects include bleeding and gastritis.[6] Other side effects may include bleeding around the spine and allergic reactions such as anaphylaxis.[6] In cases of severe bleeding, it can be reversed with the antidote, idarucizumab.[6] Use is not recommended during pregnancy or breastfeeding.[6] Compared to warfarin it has fewer interactions with other medications.[9] It is a direct thrombin inhibitor.[7]
Dabigatran was approved for medical use in the United States in 2010.[6] It is on the World Health Organization's List of Essential Medicines.[10] In 2020, it was the 306th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[11] Dabigatran is available a generic medication.[12][13]
Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.[4]
It appears to be as effective as warfarin in preventing non-hemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.[14][15][16]
In 2022, an observational metal-analysis study was performed on direct oral anticoagulants for patients with atrial fibrillation. The study found that dabigatran had comparable rates of ischemic stroke or systemic embolism, intracerebral haemorrhage, and all-cause mortality when compared to other anticoagulants like apixaban, edoxaban, and rivaroxaban. Notably, apixaban was associated with a lower risk of gastrointestinal bleeding than dabigatran and the others. This finding was generally steady for patients aged 80 years or older and those with chronic kidney disease.[17]
Dabigatran is contraindicated in patients who have active pathological bleeding, since dabigatran can increase bleeding risk and can also cause serious and potentially life-threatening bleeds.[4] Dabigatran is also contraindicated in patients who have a history of serious hypersensitivity reaction to dabigatran (e.g. anaphylaxis or anaphylactic shock).[4] The use of dabigatran should also be avoided in patients with mechanical prosthetic heart valves due to the increased risk of thromboembolic events (e.g. valve thrombosis, stroke, and myocardial infarction) and major bleeding when compared with warfarin.[4][18][19]
Current FDA guidelines states that patients with mechanical heart valves should not be using dabigatran. The safety and efficacy of Pradaxa (dabigatran) were evaluated in the European RE-ALIGN trial in 2012. RE-ALIGN was terminated early because the Pradaxa treatment group had significantly more thromboembolic events and major bleeding than warfarin and determined to be contraindicated for use in patients with mechanical heart valves.[20] Further studies are needed in order to determine effects of dabigatran on patients with bioprosthetic valves.
Dabigatran is poorly excreted in breastmilk and does not appear to require any limitations to breastfeeding.[21] However, data is limited and further studies are needed.
The most commonly reported side effect of dabigatran is gastrointestinal upset. When compared with people anticoagulated with warfarin, patients taking dabigatran had fewer life-threatening bleeds, fewer minor and major bleeds, including intracranial bleeds, but the rate of gastrointestinal bleeding was significantly higher. Dabigatran capsules contain tartaric acid, which lowers the gastric pH and is required for adequate absorption. The lower pH has previously been associated with dyspepsia; some hypothesize that this plays a role in the increased risk of gastrointestinal bleeding.[22] If a small amount of GI bleeding is diagnosed, the clinicians may consider adding H2 receptor inhibitor (H2RA), proton pump inhibitors (PPIs) and mucosal protective agent. In severe bleeding, measures include discontinuation of dabigatran immediately, and administration of prothrombin complex concentrate, packed red blood cells, fresh frozen plasma, the use of specific reversal agents such as idarucizumab for dabigatran, and emergency endoscopic management.[23]
A small but significantly increased risk of myocardial infarctions (heart attacks) has been noted when combining the safety outcome data from multiple trials.[24][25] However, conflicting evidence from another review suggested that dabigatran might not substantially increase the risk of heart attacks, or if it does, then the associated risk is relatively low.[26]
For patients with moderately reduced kidney function, lower dabigatran doses are recommended due to increased drug exposure and bleeding risk.[27][28][29] Alternative anticoagulants should be considered in severe kidney impairment due to insufficient safety and efficacy data.[28]
Dabigatran intake has also been reported to cause esophageal injury or esophagitis. In a 2016 study by Toya et al., roughly 20% of patients suffered esophageal mucosa damage.[30] It has been theorized that the tartaric-acid core in the drug adheres and damages the esophagus, and then the damaged esophageal mucosa exfoliates after peristalsis.[31] Additionally, patients with limited mobility, reduced salivary secretion, and low water consumption will increase the possibility of contact by dabigatran with the esophageal mucosa.[23]
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial showed that impairment of liver function caused by dabigatran occurred in the same frequency as warfarin.[32]
Dabigatran reversibly binds to the active site on the thrombin molecule, preventing thrombin-mediated activation of coagulation factors. Furthermore, dabigatran can inactivate thrombin even when thrombin is fibrin-bound; it reduces thrombin-mediated inhibition of fibrinolysis and, therefore, may enhance fibrinolysis.[33]
Dabigatran has a half-life of approximately 12–17 h and exerts a maximum anticoagulation effect within 2 hours after ingestion.[34] Fatty foods delay the intestinal absorption of dabigatran, although the bioavailability of the drug is unaffected.[4] Several studies have demonstrated that dabigatran plasma concentrations are reduced when co-administered with proton pump inhibitors, however it is unclear if this reduction is clinically significant.[35][36][37] Dabigatran excretion through P-glycoprotein pumps is slowed in patients taking strong p-glycoprotein pump inhibitors such as quinidine, verapamil, and amiodarone, thus raising plasma levels of dabigatran.[38]
Dabigatran is available as dabigatran etexilate mesilate, formulated as the prodrug dabigatran etexilate.[4][6][38]
Dabigatran (then compound BIBR-953) was discovered from a panel of chemicals with similar structure to benzamidine-based thrombin inhibitor α-NAPAP (N-alpha-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide), which had been known since the 1980s as a powerful inhibitor of various serine proteases, specifically thrombin, but also trypsin. Addition of ethyl ester and hexyloxycarbonyl carbamide hydrophobic side chains led to the orally absorbed prodrug, BIBR 1048 (dabigatran etexilate).[39]
In March 2008, the European Medicines Agency (EMA) granted marketing authorization for Pradaxa for the prevention of thromboembolic disease following hip or knee replacement surgery and for non-valvular atrial fibrillation.[40]
The National Health Service (NHS) in Britain authorized dabigatran for use in preventing blood clots in hip and knee replacement surgery patients. According to a BBC article in 2008, Dabigatran was expected to cost the NHS £4.20 per day, which was similar to several other anticoagulants.[41]
Initially, there was no specific way to reverse the anticoagulant effect of dabigatran in the event of a major bleeding event,[42] unlike for warfarin.[43] Since then, the dabigatran-specific antidote idarucizumab, a humanized monoclonal antibody for intravenous administration, was developed, and received Food and Drug Administration (FDA) approval in 2015.[44]
Pradaxa received a Notice of Compliance (NOC) from Health Canada in June 2008,[45] for the prevention of blood clots in patients who have undergone total hip or total knee replacement surgery. Approval for atrial fibrillation patients at risk of stroke came in October 2010.[46][47]
The U.S. Food and Drug Administration (FDA) approved Pradaxa in October 2010, for prevention of stroke in patients with non-valvular atrial fibrillation.[48][49][50][51] The approval came after an advisory committee recommended the drug for approval in September 2010,[52] although caution is still urged by some outside experts.[53]
In February 2011, the American College of Cardiology Foundation and the American Heart Association added dabigatran to their guidelines for management of non-valvular atrial fibrillation with a class I recommendation.[54]
In May 2014, the FDA reported the results of a large study comparing dabigatran with warfarin in 134,000 Medicare patients. The agency concluded that dabigatran is associated with a lower risk of overall mortality, ischemic stroke, and bleeding in the brain than warfarin. Gastrointestinal bleeding was more common in those treated with dabigatran than in those treated with warfarin. The risk of heart attack was similar between the two drugs. The FDA reiterated its opinion that dabigatran's overall risk/benefit ratio is favorable.[55]
In July 2014, a series of investigations accused the privately held Boehringer Ingelheim pharmaceutical group of withholding critical information about the need for monitoring to protect patients from severe bleeding, particularly in the elderly. Review of internal communications between Boehringer researchers and employees by the FDA and the EMA revealed that Boehringer researchers had found evidence that serum levels of dabigatran vary widely. The BMJ investigation suggested that Boehringer had a financial motive to withhold this concern from regulatory health agencies because the data conflicted with their extensive marketing of dabigatran as an anticoagulant that does not require monitoring.[56][57] In August 2012, Pradaxa claims filed in U.S. federal courts were consolidated into a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. In May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug was alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.[58]
Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity.
Defunct US film distribution and production company The Geffen CompanyThe Geffen Film Company, Inc.Geffen PicturesGeffen Pictures logoTypeFilm distributor and production companyIndustryMotion picturesFounded1982; 41 years ago (1982)[1]FounderDavid GeffenDefunct1998; 25 years ago (1998)FateClosedSuccessorsDreamWorks PicturesLibrary:Warner Bros.Paramount Pictures(through MTV Entertainment Studios)(Beavis and Butt-Head Do America only)Disney–ABC Domesti…
Nota: Para outras cidades com este nome, veja Bellini. Coordenadas: 45° 16' N 9° 6' E Vellezzo Bellini Comuna Localização Vellezzo BelliniLocalização de Vellezzo Bellini na Itália Coordenadas 45° 16' N 9° 6' E Região Lombardia Província Pavia Características geográficas Área total 7 km² População total 2 251 hab. Densidade 322 hab./km² Altitude 94 m Outros dados Comunas limítrofes Battuda, Certosa di Pavia, Giu…
Pour les articles homonymes, voir James Arthur (homonymie) et Arthur. James Arthur Données clés Nom de naissance James Arthur Naissance 2 mars 1988 (35 ans) Activité principale Chanteur, musicien, auteur-compositeur Genre musical Pop, soul, hip-hop, Electro pop Instruments Voix, piano, guitare Années actives Depuis 2012 Labels Syco Music modifier James Arthur, né le 2 mars 1988 à Middlesbrough (Angleterre), est un chanteur et artiste britannique ayant remporté la 9e saison du t
Кишинівська духовна семінарія Дата заснування 1813 Конфесія православ'я Розташування Молдова, Кишинів Кишинівська духо́вна семіна́рія (молд. Seminarul Teologic din Chișinău) — навчальний заклад Молдовської митрополії Відомства православного сповідання Російської імперії …
List of events in the year 1324 ← 1323 1322 1321 1320 1319 1324 in Ireland → 1325 1326 1327 1328 1329 Centuries: 12th 13th 14th 15th 16th Decades: 1300s 1310s 1320s 1330s 1340s See also:Other events of 1324 List of years in Ireland Events from the year 1324 in Ireland. Incumbent Lord: Edward II Events The same cow-destruction (namely, the Maeldornnaigh) prevailed throughout Ireland.[1] Archbishop Ledrede of Ossory accuses Alice Kyteler and her associates of witchcraft and her…
Квока Охоронний статус Уразливий (МСОП 3.1) Біологічна класифікація Царство: Тварини (Animalia) Тип: Хордові (Chordata) Клада: Синапсиди (Synapsida) Клас: Ссавці (Mammalia) Інфраклас: Сумчасті (Marsupialia) Ряд: Diprotodontia Родина: Кенгурові (Macropodidae) Підродина: Macropodinae Рід: Квока (Setonix)Lesson, 1842 Вид: Квока (S.…
هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (ديسمبر 2019) سليم الأفنيش معلومات شخصية الميلاد 20 نوفمبر 1948 (75 سنة) النقب مواطنة ألمانيا الحياة العملية المدرسة الأم جامعة هايدلبرغ المهنة كاتب اللغات ال
Grafik yang menggambarkan hukum Yerkes-Dodson Hukum Yerkes–Dodson adalah keterkaitan empiris antara stres dengan performa. Hukum ini pertama kali dikembangkan oleh psikolog Robert M. Yerkes dan John Dillingham Dodson pada tahun 1908.[1] Menurut hukum ini, performa akan meningkat seiring dengan peningkatan gairah fisiologis atau kejiwaan, tetapi hanya sampai pada titik tertentu. Jika tingkat kegairahan terlalu tinggi, performa akan berkurang. Proses ini sering kali digambarkan dengan gr…
Ignaz SchwinnBiographieNaissance 1er avril 1860HardheimDécès 31 août 1948 (à 88 ans)ChicagoSépulture Cimetière de RosehillNationalité allemandeActivité Homme d'affairesVue de la sépulture.modifier - modifier le code - modifier Wikidata Badge de fourche Arnold Schwinn Ignaz Schwinn (1860-1948) était un concepteur, le cofondateur et propriétaire de la Schwinn Bicycle Company. Biographie Ignaz Schwinn est né en 1860 en Allemagne dans la ville de Hardheim. Durant sa jeunesse il comp…
سيد لوسيرو معلومات شخصية اسم الولادة (باللغات المتعددة: Timothy Mark Pimentel Eigenmann) الميلاد 12 مارس 1981 (42 سنة) مانيلا مواطنة الفلبين الأب مارك جيل الحياة العملية المهنة عارض، وممثل، وممثل أفلام، وممثل تلفزيوني اللغات الفلبينية المواقع IMDB صفحته على IMDB&…
American politician Connie McCready46th Mayor of Portland, OregonIn officeSeptember 5, 1979 – November 24, 1980Preceded byNeil GoldschmidtSucceeded byFrank IvanciePortland City CommissionerIn officeMarch 19, 1970 – September 5, 1979Preceded byStanley W. EarlSucceeded byMike LindbergMember of the Oregon House of Representativesfrom the 6th districtIn office1967–1969 Personal detailsBorn(1921-08-20)August 20, 1921Pendleton, Oregon, U.S.[1]DiedDecember 22…
This article is about the 1972 film. For the topic, see Ripoff. For other uses, see Rip off (disambiguation). 1972 American filmRipped OffDVD cover for 'Ripped Off'Directed byFranco ProsperiWritten byLucio BattistradaAdriano BolzoniArmando CrispinoDon Carlos DunawayProduced byOttavio OppoStarringRobert BlakeErnest BorgnineCinematographyGábor PogányEdited byAlberto GallittiFima NoveckMusic byCarlos PesDistributed byTroma EntertainmentRelease date 1972 (1972) Running time83 minutesCountries…
Finnish animated TV series For the former video streaming service, see Toons.TV. Angry Birds ToonsGenre Comedy Adventure Silent comedy Slapstick Cartoon series Created byMikael HedLauri KonttoriMikko PölläBased onAngry Birdsby Rovio EntertainmentDeveloped bySøren FlengVoices of Antti LJ Pääkkönen Antti Pääkkönen Pasi Ruohonen Lynne Guaglione Helja Heikkinen Rauno Ahonen Chris Sadler Opening themeAngry Birds ToonsComposers Mike Reagan David Schweitzer Benny Oschmann Alexander Röder Doug…
Mabuchi Motor CompanyMabuchi Motor head officeNative nameマブチモーター株式会社TypePublicTraded asTYO: 6592IndustrySmall DC motorsPredecessorKansai Rika Kenkyusho (a scientific research institute), followed by Tokyo Science Industrial Co. Ltd., Japan Science and Industry Co. Ltd., Mabuchi Shoji Co. Ltd., Mabuchi Industrial Co., Ltd., and Tokyo Science Co., Ltd.Founded1946; 77 years ago (1946)FounderKenichi MabuchiHeadquarters430 Matsuhidai 270-2280, Matsudo, Chiba, J…
Welcome! Hello, Pedrortm, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Unfortunately, one or more of the pages you created, like Instituto de Pensamiento Estratégico Ágora (IPEA), may not conform to some of Wikipedia's guidelines for page creation, and may soon be deleted (if it hasn't already). There's a page about creating articles you may want to read called Your first article. If you are stuck, and looking for help, please come t…
South Korean para table tennis player Kim Kyung-mookKim at the 2010 World Para Table Tennis ChampionshipsPersonal informationBorn (1965-02-19) February 19, 1965 (age 58)Cheongju,[1] North Chungcheong,[2] South KoreaHeight170 cm (5 ft 7 in)[2]Weight70 kg (154 lb)[1]Table tennis career Playing styleRight-handed shakehand gripDisability class2Highest ranking1 (March 1998)[3]Current ranking23 (February 2020) Me…
Car model Motor vehicle Tofaş ŞahinTofaş Şahin in EgyptOverviewManufacturerTofaşAlso calledTofaş DoğanTofaş Kartal (station wagon)Nasr SahinHolland DOCCProduction1981–2010AssemblyBursa, TurkeyCairo, Egypt (Nasr, until 2010)Addis Ababa, Ethiopia (Holland Car, until 2010)Body and chassisClassFamily carBody style4-door sedan 5-door station wagon (Kartal)LayoutFR layoutRelatedFiat 131SEAT 131PowertrainEngineGasoline: 1,297 cc (79.1 cu in) 131 A0.000 OHV I4 1,585…
Narrative subgenre Psychological horror is a subgenre of horror and psychological fiction with a particular focus on mental, emotional, and psychological states to frighten, disturb, or unsettle its audience. The subgenre frequently overlaps with the related subgenre of psychological thriller, and often uses mystery elements and characters with unstable, unreliable, or disturbed psychological states to enhance the suspense, horror, drama, tension, and paranoia of the setting and plot and to prov…
觀氣道服 此條目需要擴充。 (2015年3月6日)请協助改善这篇條目,更進一步的信息可能會在討論頁或扩充请求中找到。请在擴充條目後將此模板移除。 觀氣道(越南語:Quán Khí Đạo),是一門越南武術,由越南武術家范春從(法语:Pham Xuân Tong)于1981年在法国创立[1]。观气道融合了中国武术、越南武术和欧洲文化的特点,并有观气道武门世界联合会成立。 參考 ^ Habersetz…
King of England from 1413 to 1422 Henry VMiniature in the Regement of Princes by Thomas Hoccleve, c. 1411–1413King of England (more...) Reign21 March 1413 – 31 August 1422Coronation9 April 1413PredecessorHenry IVSuccessorHenry VIRegent of FranceRegency21 May 1420 – 31 August 1422MonarchCharles VIBorn16 September 1386Monmouth Castle, Wales, Kingdom of EnglandDied31 August 1422 (aged 35)Château de Vincennes, Kingdom of FranceBurial7 November 1422Westminster Abbey, LondonSpouse Cat…
Lokasi Pengunjung: 3.141.45.83